China Medicine Corporation (CHME)

[barsell]

The third and final stage consists of the Investor subscribing for up to $27.8 million, according to the needs of China Medicine, in newly issued shares of China Medicine common stock at a price of $2.60 per share... . China Medicine anticipates using the proceeds from stage one to replenish working capital used to acquire LifeTech. The Company anticipates using proceeds from stage two of this investment for expanding LifeTech's manufacturing capabilities and for general working capital purposes. Proceeds from the third stage are expected to be used to acquire additional pharmaceutical companies once identified and agreed upon by the Investor.

Above quote taken from news report not SEC report as I said...sorry